Literature DB >> 3094061

Effect of ceruletide on tardive dyskinesia: a pilot study of quantitative computer analyses on electromyogram and microvibration.

T Nishikawa, M Tanaka, A Tsuda, H Kuwahara, I Koga, Y Uchida.   

Abstract

Seven patients with bucco-lingual dyskinesia were treated with a single dose of ceruletide 0.8 micrograms/kg IM, a potent analogue of cholecystokinin octapeptide. Time-course effects of the drug were then followed up to 6 weeks after injection in the longest case. To assess changes in severity of dyskinesia objectively, electromyogram and microvibration were recorded. These data were subjected to the Fast Fourier Transform and an averaged power spectrum was computed. The effect of ceruletide on dyskinesia within 2 h after injection differed (three cases: inhibitory, two cases: facilitatory, two cases: no effect). It was notable that a long-lasting inhibitory effect of this peptide was observed in two severe irreversible cases. The present findings might contribute to further understanding of the physiopathophysiological role of cholecystokinin-like peptides in the brain and to practical treatment of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094061     DOI: 10.1007/bf00172862

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia.

Authors:  J Gerlach; N Reisby; A Randrup
Journal:  Psychopharmacologia       Date:  1974-01-09

2.  Polygraphic profile of oral tardive dyskinesia and of rabbit syndrome: for quantitative and qualitative evaluation.

Authors:  K Jus; A Jus; A Villeneuve
Journal:  Dis Nerv Syst       Date:  1973-01

3.  History and definition of tardive dyskinesia.

Authors:  D Tarsy
Journal:  Clin Neuropharmacol       Date:  1983-06       Impact factor: 1.592

4.  Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons.

Authors:  L R Skirboll; A A Grace; D W Hommer; J Rehfeld; M Goldstein; T Hökfelt; B S Bunney
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

5.  No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.

Authors:  F Lotstra; P Verbanck; J Mendlewicz; J J Vanderhaeghen
Journal:  Biol Psychiatry       Date:  1984-06       Impact factor: 13.382

6.  Ceruletide: a new drug for the treatment of schizophrenic patients?

Authors:  M Albus; M Ackenheil; U Münch; D Naber
Journal:  Arch Gen Psychiatry       Date:  1984-05

7.  Long-lasting reduction of amphetamine-induced hyperactivity in rats after combined administration of caerulein with haloperidol.

Authors:  K Matsubara; A Matsushita
Journal:  Eur J Pharmacol       Date:  1984-05-18       Impact factor: 4.432

8.  Cholecystokinin in the nucleus of the solitary tract of the rat: evidence for its vagal origin.

Authors:  M Palkovits; J Z Kiss; M C Beinfeld; T H Williams
Journal:  Brain Res       Date:  1982-12-09       Impact factor: 3.252

9.  Ceruletide resembles antipsychotics in rats and schizophrenic patients. Preliminary report.

Authors:  J M van Ree; W M Verhoeven; G J Brouwer; D de Wied
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

10.  Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia.

Authors:  T Moroji; N Watanabe; N Aoki; S Itoh
Journal:  Arch Gen Psychiatry       Date:  1982-04
View more
  2 in total

1.  Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists.

Authors:  A J Stoessl; C T Dourish; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Sweat function in Parkinson's disease.

Authors:  Y Mano; T Nakamuro; T Takayanagi; R F Mayer
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.